Beata Sieklucka
Overview
Explore the profile of Beata Sieklucka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
83
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Baran A, Nowowiejska J, Hermanowicz J, Sieklucka B, Krahel J, Kiluk P, et al.
J Clin Med
. 2022 Sep;
11(17).
PMID: 36078974
Psoriasis is one of the most common dermatoses, which shortens patients’ lives because of the wide comorbidity. However, little is known about its association with neurodegenerative diseases (NDs). We aimed...
12.
Nowowiejska J, Baran A, Hermanowicz J, Sieklucka B, Krahel J, Kiluk P, et al.
J Clin Med
. 2022 May;
11(9).
PMID: 35566558
Psoriasis and neurodegenerative diseases (NDs) are important medical, social and economic issues. The possible relationship of psoriasis and NDs has not been established yet. This study involved 60 patients with...
13.
Hermanowicz J, Kalaska B, Pawlak K, Sieklucka B, Miklosz J, Mojzych M, et al.
Pharmaceutics
. 2021 Aug;
13(8).
PMID: 34452183
MM-129 is a novel inhibitor targeting BTK/PI3K/AKT/mTOR and PD-L1, as it possesses antitumor activity against colon cancer. To evaluate the safety profile of MM-129, we conducted a toxicity study using...
14.
Sieklucka B, Pawlak D, Domaniewski T, Hermanowicz J, Lipowicz P, Doroszko M, et al.
Cytokine
. 2021 Aug;
148:155685.
PMID: 34411988
The progression of chronic kidney disease (CKD) in children is associated with deregulated parathyroid hormone (PTH), growth retardation, and low bone accrual. PTH can cause both catabolic and anabolic impact...
15.
Pawlak K, Sieklucka B, Pawlak D
Int J Mol Sci
. 2021 Jul;
22(12).
PMID: 34207309
Secondary hyperparathyroidism and abnormalities in tryptophan (TRP) metabolism are commonly observed in chronic kidney disease (CKD). The present study aimed to establish potential interactions between endogenous parathyroid hormone (PTH) and...
16.
Hermanowicz J, Pawlak K, Sieklucka B, Czarnomysy R, Kwiatkowska I, Kazberuk A, et al.
Cancers (Basel)
. 2021 Jul;
13(13).
PMID: 34206937
Background And Aims: The purpose of the present study was to examine the pharmacodynamics features of MM-129 (1,2,4-triazine derivative) as a novel promising drug candidate against colon cancer. Methods: MM-129...
17.
Zieminska M, Sieklucka B, Pawlak K
Nutrients
. 2021 Apr;
13(3).
PMID: 33804453
Vitamin K (VK) and vitamin D (VD) deficiency/insufficiency is a common feature of chronic kidney disease (CKD), leading to impaired bone quality and a higher risk of fractures. CKD patients,...
18.
Hermanowicz J, Szymanowska A, Sieklucka B, Czarnomysy R, Pawlak K, Bielawska A, et al.
J Enzyme Inhib Med Chem
. 2021 Feb;
36(1):535-548.
PMID: 33522320
Colorectal cancer (CRC) is the third leading cause of cancer-related deaths in men and in women. The impact of the new pyrazolo[4,3-]tetrazolo[1,5-][1,2,4]triazine sulphonamide () was evaluated against human colon cancer...
19.
Rzepka Z, Rok J, Kowalska J, Banach K, Hermanowicz J, Beberok A, et al.
Cells
. 2020 Oct;
9(10).
PMID: 33050187
Cobalamin deficiency affects human physiology with sequelae ranging from mild fatigue to severe neuropsychiatric abnormalities. The cellular and molecular aspects of the nervous system disorders associated with hypovitaminosis B12 remain...
20.
Rozkiewicz D, Hermanowicz J, Tankiewicz-Kwedlo A, Sieklucka B, Pawlak K, Czarnomysy R, et al.
J Enzyme Inhib Med Chem
. 2020 Sep;
35(1):1697-1711.
PMID: 32912025
Recombinant human erythropoietin (Epo) is an effective and convenient treatment for cancer-related anaemia. In our study for the first time, we evaluated the effect of simultaneous use of Epo and...